ArticleNanoscale advances2026
Efficient naphthalene removal
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A Ni/Co bimetallic metal-organic framework (MOF) photocatalyst was synthesized and applied for the degradation of naphthalene in an aqueous solution under UV irradiation. The prepared MOF was characterized using XRD, FT-IR spectroscopy, FESEM, HRTEM, XPS, and BET analyses and TGA. Structural analyses confirmed the formation of cubic-shaped particles with a uniform shape, and Co and Ni were present in the +3 and +2 oxidation states, respectively. The prepared MOF showed excellent photocatalytic activity, achieving a maximum naphthalene degradation efficiency of 94.9% in 100 min under optimized conditions. In the absence of the photocatalyst, only 5.2% removal was observed, confirming the role of the photocatalyst in the degradation. Among the tested catalyst dosages, NC-IV (40 mg) exhibited the best performance, with a pseudo-first-order rate constant of 0.0281 min
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.